In March of Yangchun, everything recovers, and the land of Jiangsu is full of vitality. On March 13, more than 200 experts from all over Jiangsu Province gathered together to participate in the multi-center clinical research kick-off meeting of ACTL targeted anti-tumor cell immune technology in the treatment of non-small cell lung cancer at the East China Hotel in Nanjing.
Leaders and experts from the Jiangsu Provincial Health and Family Planning Commission and the Professional Committee of Cancer Chemotherapy and Biological Therapy of Jiangsu Medical Association attended the meeting and made important speeches. The project was officially launched at about 9 am.

After the launching ceremony, Shu Yongqian, director of the Oncology Department of Jiangsu Provincial People's Hospital, introduced the multi-center project. Subsequently, Professor Liu Yong, the inventor of the ACTL technology and chief scientist of ISKCON, introduced the treatment of lung cancer with the ACTL technology, and showed a number of successful cases. The response was overwhelming! Afterwards, Professor Shu Yongqian and Professor Liu Yong interacted with the participating experts and answered the hot issues that the experts were concerned about.

Unlike other biological treatments, ACTL technology is a targeted immunotherapy. The CTL cells activated by this technology will actively identify tumor cells and launch attacks on them after being returned to the patient. Other body tissues will not be affected by CTL cells.

ACTL can be used for the treatment of most tumors, including common lung cancer, breast cancer, colorectal cancer, prostate cancer, cervical cancer, ovarian cancer, nasopharyngeal cancer, esophageal cancer, kidney cancer, bladder cancer, stomach cancer, pancreatic cancer, melanoma , Lymphoma and multiple myeloma and other malignant tumors.

ACTL technology can remove tumor lesions and reduce the level of serum tumor markers, which is of great help in preventing recurrence, prolonging survival, and improving quality of life. The treatment route is intravenous infusion, which is less traumatic and painless. ACTL therapy has high safety and low side effects, which can be tolerated by most patients.